Adrenomyeloneuropathy

Related Subjects: |Adrenal Physiology |Addisons Disease |Phaeochromocytoma |Adrenal Adenomas |Adrenal Cancer |Cushing Syndrome |Cushing Disease |Congenital Adrenal hyperplasia |Primary hyperaldosteronism (Conn's syndrome) |ACTH |McCune Albright syndrome

🧾 About

• Adrenomyeloneuropathy (AMN) is an X-linked recessive peroxisomal disorder → affects mainly men, but female carriers may show late-onset symptoms.
• Considered the “milder adult form” of Adrenoleukodystrophy (ALD).
• Pathology: accumulation of very long-chain fatty acids (VLCFAs) → progressive damage to adrenal glands, spinal cord & peripheral nerves.

🧠 Clinical Presentation

• 🚶 Slowly progressive paraparesis: Lower limb weakness, gait disturbance, spasticity.
• 🧔 Hypogonadism & impotence: Low testosterone, sexual dysfunction.
• 🚽 Sphincter disturbance: Urinary urgency, incontinence, bowel dysfunction.
• ⚡ Adrenal insufficiency (Addison’s disease): Fatigue, low BP, muscle weakness, hyperpigmentation.
• 🦶 Axonal neuropathy: Sensory loss, neuropathic pain.
• 🎵 Disturbed vibration sense: Common in legs → indicates spinal cord involvement.

🔎 Investigations

• 🩸 Cortisol & Synacthen test: Low cortisol + inadequate ACTH response → adrenal insufficiency.
• 🖥️ MRI brain/spinal cord: Demyelination in cord & brainstem typical of AMN.
• 🧪 VLCFA assay: Elevated very long-chain fatty acids → biochemical hallmark.
• 🧬 Genetic testing: ABCD1 gene mutation (codes peroxisomal transporter protein).

💊 Management

• 🌟 Adrenal replacement: Lifelong glucocorticoids ± mineralocorticoids for Addison’s disease.
• 🥤 Lorenzo’s Oil: Mix of unsaturated fatty acids → may reduce VLCFA levels, but benefit in AMN is limited/controversial.
• 🦽 Symptom control: Physio, mobility aids, baclofen/tizanidine for spasticity, meds for neuropathic pain.
• 🧔 Hormone therapy: Testosterone replacement if hypogonadism present.
• 🧬 Emerging therapies: Gene therapy trials targeting ABCD1 gene are ongoing.

📊 Prognosis

• Life expectancy often preserved, but progressive neurological disability is common.
• Disability usually due to spastic paraparesis, sphincter dysfunction, and neuropathy.
• Adrenal failure is life-threatening if untreated → always replace steroids early.

📌 Exam Pearls

• 🧬 AMN = X-linked peroxisomal disorder with VLCFA accumulation.
• 🚨 Always check adrenal function (low cortisol may be first clue).
• 👣 Spastic paraparesis + sphincter disturbance = classic presentation.
• 🩸 Synacthen test + VLCFA assay + ABCD1 gene testing → diagnostic triad.
• 🌍 Remember female carriers → may present later with mild spastic paraparesis.

Cases — Adrenomyeloneuropathy (AMN)

• Case 1 — Adult-onset spastic paraparesis 🚶: A 32-year-old man presents with progressive stiffness and weakness of both legs, urinary urgency, and erectile dysfunction. Exam: spastic paraparesis with brisk reflexes. Endocrine screen: low cortisol, high ACTH. Diagnosis: AMN with adrenal insufficiency. Managed with glucocorticoid replacement, physiotherapy, and symptomatic management.
• Case 2 — Adrenal-only presentation 🧪: A 25-year-old man presents with recurrent fatigue, skin hyperpigmentation, and postural dizziness. Exam: low BP, tanned skin. Bloods: low morning cortisol, elevated ACTH. No neurological symptoms yet. Genetic testing: ABCD1 mutation (X-linked adrenoleukodystrophy). Diagnosis: adrenal variant of AMN. Managed with steroid replacement and genetic counselling.
• Case 3 — Cerebral involvement 🧠: A 28-year-old man with known AMN develops behavioural changes, cognitive decline, and seizures. MRI brain: demyelination in parieto-occipital white matter. Diagnosis: AMN with cerebral involvement. Managed with supportive neurological care; bone marrow transplantation considered in early cerebral disease.

Teaching Point 🩺: Adrenomyeloneuropathy is an adult-onset phenotype of X-linked adrenoleukodystrophy (ABCD1 gene defect). Pathophysiology: accumulation of very long-chain fatty acids → adrenal insufficiency + spinal cord/nerve dysfunction. Key features: spastic paraparesis, peripheral neuropathy, bladder dysfunction, adrenal failure, ± cerebral demyelination. Diagnosis: VLCFA levels, genetic testing. Management: steroid replacement, physiotherapy, symptomatic therapy; bone marrow transplant may help cerebral disease if detected early.